Related Experiment Video

Updated: Jun 1, 2025

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
07:41

Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device

Published on: July 20, 2022

1.8K

Glucagon-Like Peptide-1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices

Boaz Elad1, Changhee Lee1, Afsana Rahman1

  • 1Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA.

Artificial Organs
|January 21, 2025
PubMed
Abstract

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) significantly improved weight, HbA1c, and NT-proBNP levels in durable left ventricular assist device (LVAD) patients. GLP-1 RA therapy demonstrated safety and efficacy, with low adverse events in this population.

Area of Science:

  • Cardiology and Endocrinology
  • Advanced Heart Failure Management
  • Mechanical Circulatory Support

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are known to improve cardiometabolic outcomes.
  • Limited data exists on the safety and efficacy of GLP-1 RAs in patients with advanced heart failure requiring durable left ventricular assist devices (LVADs).

Purpose of the Study:

  • To evaluate the safety and efficacy of GLP-1 RA therapy in patients supported by durable LVADs.
  • To assess the impact of GLP-1 RA on cardiometabolic parameters and adverse events in LVAD recipients.

Main Methods:

  • A single-center retrospective analysis was performed on patients with durable LVAD support who were treated with GLP-1 RA.
  • Outcomes assessed included cardiometabolic efficacy and adverse events related to LVAD and GLP-1 RA therapy up to one year post-initiation.

Main Results:

  • Forty LVAD patients received GLP-1 RA therapy between 2018 and 2023.
  • At one-year follow-up, significant improvements were observed in patient weight (p < 0.001), HbA1c (p = 0.003), and NT-proBNP levels (p = 0.04).
  • GLP-1 RA therapy was not associated with changes in cannula position, and LVAD complication rates were low, with no drug interruptions due to adverse events.

Conclusions:

  • Durable LVAD patients treated with GLP-1 RA exhibited improved cardiometabolic profiles and a low incidence of major adverse events.
  • GLP-1 RA therapy shows promise as an adjunctive treatment in LVAD recipients, potentially improving hemodynamics and future transplant candidacy.
Keywords:
glucagon‐like peptide‐1 receptor agonistsheart failureleft ventricular assist deviceobesity

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K
Sustained Administration of &#946;-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

7.2K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
510
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
165
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
376
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136